A Phase 2 interventional study of SPD489 (lisdexamfetamine dimesylate) and Placebo matching SPD489 (lisdexamfetamine dimesylate) in Schizophrenia and Predominant Negative Symptoms, sponsored by Shire. Completed at 27 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-06-09.
Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Schizophrenia by Takeda — none open to participants now, none under way, none of them phase 3. Schizophrenia · Takeda.
Among the 11 studies in Schizophrenia by Takeda, this one is the 2nd largest by enrollment, is the only one that started in 2009, is one of 2 in phase 2, and was the 1st registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →None of the 11 studies in Schizophrenia by Takeda is open now. The open studies under Schizophrenia, anywhere →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 92 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 20 across the 11 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Schizophrenia by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To explore the efficacy of SPD489, as adjunctive therapy to a stable dose of atypical antipsychotic medication, on negative symptoms in adult subjects with clinically stable schizophrenia and predominant negative symptoms, as measured by the Scale for the Assessment of Negative Symptoms (SANS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: SPD489 (lisdexamfetamine dimesylate)
Placebo
Drug: Placebo matching SPD489 (lisdexamfetamine dimesylate)
oral, 20, 30, 40, 50, 60, or 70 mg once daily
Also known as: Vyvanse
oral, once daily
Change From Open-label Baseline in Modified Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Week 10 Open-label Phase, Last Observation Carried Forward (LOCF)
The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.
Time frame: Open-label Baseline and Week 10 Open-label Phase
Change From Double-blind Randomization Baseline in SANS-18 Total Score at Week 4 Double-blind Phase, Termination Observation Carried Forward (TOCF)
The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.
Time frame: Double-blind Randomization Baseline and Week 4 Double-blind Phase
Percent of Participants In Open-label Phase Who Were SANS-18 Responders at Week 10 Open-label Phase
Response is defined as reduction in total SANS score of greater than or equal to 20%. The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.
Time frame: Week 10 Open-label Phase
Percent of Participants In Double-blind Phase Who Maintained SANS-18 Response at Week 4 Double-blind Phase
Response is defined as reduction in total SANS score of greater than or equal to 20%. The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.
Time frame: Week 4 Double-blind Phase
Change From Open-label Baseline in SANS Global Scores at Week 10 Open-label Phase
The SANS assesses 5 symptom complexes to rate the negative symptoms of subjects. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.
Time frame: Open-label Baseline and Week 10 Open-label Phase
Change From Double-blind Randomization Baseline in SANS Global Scores at Week 4 Double-blind Phase
The SANS assesses 5 symptom complexes to rate the negative symptoms of subjects. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.
Time frame: Double-blind Randomization Baseline and Week 4 Double-blind Phase
Change From Open-label Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at Week 10 Open-label Phase, LOCF
The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment.
Time frame: Open-label Baseline and Week 10 Open-label Phase
Change From Double-blind Randomization Baseline in PANSS Scores at Week 4 Double-blind Phase, TOCF
The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment.
Time frame: Double-blind Randomization Baseline and Week 4 Double-blind Phase
Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Open-label Baseline
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
Time frame: Open-label Baseline
Percent of Participants With CGI-S at Week 10 Open-label Phase
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
Time frame: Week 10 Open-label Phase
Percent of Participants With CGI-S at Double-blind Randomization Baseline
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
Time frame: Double-blind Randomization Baseline
Percent of Participants With CGI-S at Week 4 Double-blind Phase
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
Time frame: Week 4 Double-blind Phase
Percent of Participants With Improvement on Clinical Global Impression - Change (CGI-C) at Week 10 Open-label Phase
CGI-C permits a global evaluation of the change of the subject's overall schizophrenia condition over time. It consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
Time frame: Open-label Phase Week 10
Percent of Participants With Improvement on CGI-C at Week 4 Double-blind Phase
CGI-C permits a global evaluation of the change of the subject's overall schizophrenia condition over time. It consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
Time frame: Double-blind Phase Week 4
Change From Open-label Baseline in the Brief Assessment of Cognition in Schizophrenia (BACS) Total Score at Week 10 Open-label Phase
BACS measures attention and speed of processing, and the test score is the total number correct. The measure of the test is the number of correct numerals where subjects write numerals 1-9 as matches to nonmeaningful symbols on a response sheet for 90 seconds, based upon a key provided to them.
Time frame: Open-label Baseline and week 10 Open-label Phase
Change From Double-blind Randomization Baseline in BACS Total Score at Week 4 Double-blind Phase
BACS measures attention and speed of processing, and the test score is the total number correct. The measure of the test is the number of correct numerals where subjects write numerals 1-9 as matches to nonmeaningful symbols on a response sheet for 90 seconds, based upon a key provided to them.
Time frame: Double-blind Randomization Baseline and Week 4
Change From Open-label Baseline in Letter-Number Span Test (LNS) Total Score at Week 10 Open-label Phase
LNS is a test of verbal working memory. Subjects are presented with a sequence of numbers and letters aurally and then asked to tell the rater the numbers first from lowest to highest followed by the letters in alphabetical sequence. The measure is the number of correct sequences.
Time frame: Open-label Baseline and week 10 Open-label Phase
Change From Double-blind Randomization Baseline in LNS Total Score at Week 4 Double-blind Phase
LNS is a test of verbal working memory. Subjects are presented with a sequence of numbers and letters aurally and then asked to tell the rater the numbers first from lowest to highest followed by the letters in alphabetical sequence. The measure is the number of correct sequences.
Time frame: Double-blind Randomization Baseline and Week 4
Change From Open-label Baseline in Hopkins Verbal Learning Test - Revised (HVLT-R) Total Score at Week 10 Open-label Phase
HVLT-R measures verbal learning. Test scores are the total number of words recalled correctly over 3 trials. The test consists of 12 nouns read aloud for 3 consecutive trials and each trial is followed by a recall test.
Time frame: Open-label Baseline and Week 10
Change From Double-blind Randomization Baseline in HVLT-R Total Scores at Week 4 Double-blind Phase
HVLT-R measures verbal learning. Test scores are the total number of words recalled correctly over 3 trials. The test consists of 12 nouns read aloud for 3 consecutive trials and each trial is followed by a recall test.
Time frame: Double-blind Randomization Baseline and week 4 Double-blind Phase
Change From Open-label Baseline in University of California Performance-Based Skills Assessment, Brief Version (UPSA-B) Scores at Week 10 Open-label Phase, LOCF
UPSA-B assesses skills in 5 areas of life functioning. It contains 2 subscales. Percentages correct on these 2 subscales are multiplied by 50. Thus, scores can range from 0 to 50 on each of these 2 subscales, and total scores can range from 0 to 100. Scores of 75 or higher are associated with independent living.
Time frame: Open-label Baseline and week 10 Open-label Phase
Change From Double-blind Randomization Baseline in UPSA-B Scores at Week 4 Double-blind Phase
UPSA-B assesses skills in 5 areas of life functioning. It contains 2 subscales. Percentages correct on these 2 subscales are multiplied by 50. Thus, scores can range from 0 to 50 on each of these 2 subscales, and total scores can range from 0 to 100. Scores of 75 or higher are associated with independent living.
Time frame: Double-blind Randomization Baseline and Week 4 Double-blind Phase
Change From Open-label Baseline in Behavioral Rating Inventory of Executive Function - Adult Version (BRIEF-A) T-scores at Week 10 Open-label Phase
BRIEF-A is a validated 75-item questionnaire composed of three indexes (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Open-label Baseline and Week 10 Open-label Phase
Change From Double-blind Randomization Baseline in BRIEF-A T-Scores at Week 4 Double-blind Phase
BRIEF-A is a validated 75-item questionnaire composed of three indexes (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Double-blind Randomization Baseline and Week 4 Double-blind Phase
Change From Open-label Baseline in Simpson Angus Scale (SAS) Total Score at Week 10 Open-label Phase
SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment.
Time frame: Open-label Baseline and Week 10 Open-label Phase
Change From Open-label Baseline in SAS Total Score at Week 4 of Double-blind Phase
SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment.
Time frame: Open-label Baseline and Week 4 Double-blind Phase
Change From Open-label Baseline in Barnes Akathisia Scale (BAS) Scores at Week 10 Open-label Phase
BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness.
Time frame: Open-label Baseline and week 10 Open-label Phase
Change From Open-label Baseline in BAS Scores at Week 4 of Double-blind Phase
BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness.
Time frame: Open-label Baseline and Week 4 Double-blind Phase
Change From Open-label Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at Week 10 Open-label Phase
ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.
Time frame: Open-label Baseline and Week 10 Open-label Phase
Change From Double-blind Randomization Baseline in ACSA Total Score at Week 4 Double-blind Phase
ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.
Time frame: Double-blind Randomization Baseline and Week 4 Double-blind Phase
Change From Open-label Baseline in Pittsburgh Sleep Quality Index (PSQI) Total Global Score at Week 10 Open-label Phase
PSQI evaluates 7 areas of quality and pattern of sleep. Each area is rated on a scale from 0 (better) to 3 (worse) with a total score ranging from 0 to 21. Reduction in total scores are associated with better sleep quality.
Time frame: Open-label Baseline and Week 10 Open-label Phase
Change From Open-label Baseline in PSQI Total Global Score at Week 4 of Double-blind Phase
PSQI evaluates 7 areas of quality and pattern of sleep. Each area is rated on a scale from 0 (better) to 3 (worse) with a total score ranging from 0 to 21. Reduction in total scores are associated with better sleep quality.
Time frame: Open-label Baseline and Week 4 Double-blind Phase
Change From Open-label Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at Week 10 Open-label Phase
CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression.
Time frame: Open-label Baseline and Week 10 Open-label Phase
Change From Open-label Baseline in CDSS at Week 4 of Double-blind Phase
CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression.
Time frame: Open-label Baseline and Week 4 of Double-blind Phase
| Milestone | SPD489 | Placebo |
|---|---|---|
| Started | 92 | 0 |
| Completed | 69 | 0 |
| Not completed | 23 | 0 |
| Withdrew: Adverse event | 5 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 11 | 0 |
| Withdrew: Failure to meet randomization criteria | 1 | 0 |
| Withdrew: Withdrawal criteria met | 5 | 0 |
| Milestone | SPD489 | Placebo |
|---|---|---|
| Started | 34 | 35 |
| Completed | 27 | 29 |
| Not completed | 7 | 6 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Withdrawal criteria met | 1 | 1 |
| Withdrew: Noncompliance | 1 | 1 |
| Withdrew: Positive urine drug screen | 1 | 1 |
The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.
| Units on a scale | SPD489 (Open-label Phase) |
|---|---|
| Change From Open-label Baseline in Modified Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Week 10 Open-label Phase, Last Observation Carried Forward (LOCF) | -12.9 ± 10.04 |
Response is defined as reduction in total SANS score of greater than or equal to 20%. The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.
| Percent of participants | SPD489 (Open-label Phase) |
|---|---|
| Percent of Participants In Open-label Phase Who Were SANS-18 Responders at Week 10 Open-label Phase | 52.9 |
The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.
| Units on a scale | SPD489 (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Change From Double-blind Randomization Baseline in SANS-18 Total Score at Week 4 Double-blind Phase, Termination Observation Carried Forward (TOCF) | 4.5 ± 2.14 | 2.2 ± 1.85 |
Response is defined as reduction in total SANS score of greater than or equal to 20%. The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.
| Percent of participants | SPD489 (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Percent of Participants In Double-blind Phase Who Maintained SANS-18 Response at Week 4 Double-blind Phase | 71.4 | 82.4 |
The SANS assesses 5 symptom complexes to rate the negative symptoms of subjects. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.
| Units on a scale | SPD489 (Open-label Phase) |
|---|---|
| Affective Flattening | -0.9 ± 0.80 |
| Alogia | -0.9 ± 0.65 |
| Avolition-Apathy | -0.5 ± 0.81 |
| Anhedonia-Asociality | -0.7 ± 0.77 |
| Attention | -0.7 ± 0.80 |
The SANS assesses 5 symptom complexes to rate the negative symptoms of subjects. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.
| Units on a scale | SPD489 (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Affective Flattening | 0.2 ± 0.17 | 0.2 ± 0.15 |
| Alogia | 0.5 ± 0.21 | 0.0 ± 0.19 |
| Avolition-Apathy | 0.2 ± 0.16 | 0.1 ± 0.15 |
| Anhedonia-Asociality | 0.3 ± 0.18 | 0.1 ± 0.16 |
| Attention | 0.4 ± 0.18 | 0.3 ± 0.17 |
The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment.
| Units on a scale | SPD489 (Open-label Phase) |
|---|---|
| Positive subscale | -1.0 ± 2.23 |
| Negative subscale | -4.8 ± 4.01 |
| General Psychopathology subscale | -4.0 ± 5.11 |
The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment.
| Units on a scale | SPD489 (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Positive subscale | 0.5 ± 0.31 | -0.1 ± 0.31 |
| Negative subscale | 0.9 ± 0.46 | -0.1 ± 0.45 |
| General Psychopathology subscale | 0.9 ± 0.78 | -0.9 ± 0.77 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
| Percent of participants | SPD489 (Open-label Phase) |
|---|---|
| Normal, not at all ill | 0 |
| Borderline mentally ill | 0 |
| Mildly ill | 29.3 |
| Moderately ill | 55.4 |
| Markedly ill | 14.1 |
| Severely ill | 1.1 |
| Among the most extremely ill | 0 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
| Percent of participants | SPD489 (Open-label Phase) |
|---|---|
| Normal, not at all ill | 0 |
| Borderline mentally ill | 2.9 |
| Mildly ill | 54.3 |
| Moderately ill | 38.6 |
| Markedly ill | 4.3 |
| Severely ill | 0 |
| Among the most extremely ill | 0 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
| Percent of participants | SPD489 (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Normal, not at all ill | 0 | 0 |
| Borderline mentally ill | 2.9 | 2.9 |
| Mildly ill | 50.0 | 60.0 |
| Moderately ill | 38.2 | 37.1 |
| Markedly ill | 8.8 | 0 |
| Severely ill | 0 | 0 |
| Among the most extremely ill | 0 | 0 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
| Percent of participants | SPD489 (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Normal, not at all ill | 0 | 0 |
| Borderline mentally ill | 3.4 | 13.8 |
| Mildly ill | 34.5 | 69.0 |
| Moderately ill | 48.3 | 13.8 |
| Markedly ill | 13.8 | 3.4 |
| Severely ill | 0 | 0 |
| Among the most extremely ill | 0 | 0 |
CGI-C permits a global evaluation of the change of the subject's overall schizophrenia condition over time. It consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
| Percent of participants | SPD489 (Open-label Phase) |
|---|---|
| Percent of Participants With Improvement on Clinical Global Impression - Change (CGI-C) at Week 10 Open-label Phase | 30.0 |
CGI-C permits a global evaluation of the change of the subject's overall schizophrenia condition over time. It consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
| Percent of participants | SPD489 (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Percent of Participants With Improvement on CGI-C at Week 4 Double-blind Phase | 17.2 | 27.6 |
BACS measures attention and speed of processing, and the test score is the total number correct. The measure of the test is the number of correct numerals where subjects write numerals 1-9 as matches to nonmeaningful symbols on a response sheet for 90 seconds, based upon a key provided to them.
| correct numerals | SPD489 (Open-label Phase) |
|---|---|
| Change From Open-label Baseline in the Brief Assessment of Cognition in Schizophrenia (BACS) Total Score at Week 10 Open-label Phase | 2.3 ± 8.92 |
BACS measures attention and speed of processing, and the test score is the total number correct. The measure of the test is the number of correct numerals where subjects write numerals 1-9 as matches to nonmeaningful symbols on a response sheet for 90 seconds, based upon a key provided to them.
| correct numerals | SPD489 (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Change From Double-blind Randomization Baseline in BACS Total Score at Week 4 Double-blind Phase | 0.1 ± 1.19 | -2.7 ± 1.21 |
LNS is a test of verbal working memory. Subjects are presented with a sequence of numbers and letters aurally and then asked to tell the rater the numbers first from lowest to highest followed by the letters in alphabetical sequence. The measure is the number of correct sequences.
| correct sequences | SPD489 (Open-label Phase) |
|---|---|
| Change From Open-label Baseline in Letter-Number Span Test (LNS) Total Score at Week 10 Open-label Phase | 0.8 ± 7.72 |
LNS is a test of verbal working memory. Subjects are presented with a sequence of numbers and letters aurally and then asked to tell the rater the numbers first from lowest to highest followed by the letters in alphabetical sequence. The measure is the number of correct sequences.
| correct sequences | SPD489 (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Change From Double-blind Randomization Baseline in LNS Total Score at Week 4 Double-blind Phase | -0.1 ± 1.26 | 1.3 ± 1.28 |
HVLT-R measures verbal learning. Test scores are the total number of words recalled correctly over 3 trials. The test consists of 12 nouns read aloud for 3 consecutive trials and each trial is followed by a recall test.
| words recalled | SPD489 (Open-label Phase) |
|---|---|
| Change From Open-label Baseline in Hopkins Verbal Learning Test - Revised (HVLT-R) Total Score at Week 10 Open-label Phase | 0.7 ± 7.54 |
HVLT-R measures verbal learning. Test scores are the total number of words recalled correctly over 3 trials. The test consists of 12 nouns read aloud for 3 consecutive trials and each trial is followed by a recall test.
| words recalled | SPD489 (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Change From Double-blind Randomization Baseline in HVLT-R Total Scores at Week 4 Double-blind Phase | -1.5 ± 1.01 | 1.0 ± 1.01 |
UPSA-B assesses skills in 5 areas of life functioning. It contains 2 subscales. Percentages correct on these 2 subscales are multiplied by 50. Thus, scores can range from 0 to 50 on each of these 2 subscales, and total scores can range from 0 to 100. Scores of 75 or higher are associated with independent living.
| Scores on a scale | SPD489 (Open-label Phase) |
|---|---|
| Total Skills | 6.2 ± 12.20 |
| Communication Skills | 3.7 ± 8.56 |
| Financial Skills | 2.5 ± 7.45 |
UPSA-B assesses skills in 5 areas of life functioning. It contains 2 subscales. Percentages correct on these 2 subscales are multiplied by 50. Thus, scores can range from 0 to 50 on each of these 2 subscales, and total scores can range from 0 to 100. Scores of 75 or higher are associated with independent living.
| Scores on a scale | SPD489 (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Total Skills | -1.5 ± 1.35 | 0.0 ± 1.37 |
| Communication Skills | -1.5 ± 1.14 | -0.6 ± 1.16 |
| Financial Skills | -0.3 ± 0.83 | 0.9 ± 0.84 |
BRIEF-A is a validated 75-item questionnaire composed of three indexes (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-scores | SPD489 (Open-label Phase) |
|---|---|
| Global Executive Composite | -3.9 ± 13.29 |
| Behavioral Recognition Index | -3.1 ± 12.89 |
| Metacognition Index | -3.9 ± 13.12 |
BRIEF-A is a validated 75-item questionnaire composed of three indexes (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-scores | SPD489 (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Global Executive Composite | -1.7 ± 1.19 | -1.2 ± 1.12 |
| Behavioral Recognition Index | -0.9 ± 1.22 | -1.6 ± 1.14 |
| Metacognition Index | -2.0 ± 1.26 | -0.7 ± 1.18 |
SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment.
| Units on a scale | SPD489 (Open-label Phase) |
|---|---|
| Change From Open-label Baseline in Simpson Angus Scale (SAS) Total Score at Week 10 Open-label Phase | -0.01 ± 0.063 |
SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment.
| Units on a scale | SPD489 (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Change From Open-label Baseline in SAS Total Score at Week 4 of Double-blind Phase | 0.00 ± 0.093 | 0.00 ± 0.043 |
BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness.
| Units on a scale | SPD489 (Open-label Phase) |
|---|---|
| Objective | 0.0 ± 0.17 |
| Subjective | 0.0 ± 0.56 |
| Global | 0.0 ± 0.36 |
BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness.
| Units on a scale | SPD489 (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Objective | 0.0 ± 0.18 | -0.1 ± 0.24 |
| Subjective | 0.0 ± 0.31 | -0.1 ± 0.65 |
| Global | 0.0 ± 0.18 | -0.2 ± 0.44 |
ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.
| Units on a scale | SPD489 (Open-label Phase) |
|---|---|
| Change From Open-label Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at Week 10 Open-label Phase | -1.8 ± 9.69 |
ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.
| Units on a scale | SPD489 (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Change From Double-blind Randomization Baseline in ACSA Total Score at Week 4 Double-blind Phase | 0.4 ± 7.65 | -2.9 ± 8.75 |
PSQI evaluates 7 areas of quality and pattern of sleep. Each area is rated on a scale from 0 (better) to 3 (worse) with a total score ranging from 0 to 21. Reduction in total scores are associated with better sleep quality.
| Units on a scale | SPD489 (Open-label Phase) |
|---|---|
| Change From Open-label Baseline in Pittsburgh Sleep Quality Index (PSQI) Total Global Score at Week 10 Open-label Phase | -0.7 ± 3.15 |
PSQI evaluates 7 areas of quality and pattern of sleep. Each area is rated on a scale from 0 (better) to 3 (worse) with a total score ranging from 0 to 21. Reduction in total scores are associated with better sleep quality.
| Units on a scale | SPD489 (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Change From Open-label Baseline in PSQI Total Global Score at Week 4 of Double-blind Phase | 0.3 ± 3.01 | -1.7 ± 3.00 |
CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression.
| Units on a scale | SPD489 (Open-label Phase) |
|---|---|
| Change From Open-label Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at Week 10 Open-label Phase | -0.7 ± 2.11 |
CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression.
| Units on a scale | SPD489 (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|
| Change From Open-label Baseline in CDSS at Week 4 of Double-blind Phase | -0.1 ± 2.34 | -0.7 ± 2.30 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SPD489 (Open-label Phase) | — | 3/92 (3.3%) | 56/92 (60.9%) |
| SPD489 (Double-blind Phase) | — | 1/34 (2.9%) | 11/34 (32.4%) |
| Placebo (Double-blind Phase) | — | 2/35 (5.7%) | 7/35 (20%) |
| Event | SPD489 (Open-label Phase) | SPD489 (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|---|
| SchizophreniaPsychiatric disorders | 1/92 | 1/34 | 1/35 |
| DyspepsiaGastrointestinal disorders | 0/92 | 0/34 | 1/35 |
| Chest painGeneral disorders | 1/92 | 0/34 | 0/35 |
| HallucinationPsychiatric disorders | 1/92 | 0/34 | 0/35 |
| Major depressionPsychiatric disorders | 1/92 | 0/34 | 0/35 |
| Event | SPD489 (Open-label Phase) | SPD489 (Double-blind Phase) | Placebo (Double-blind Phase) |
|---|---|---|---|
| HeadacheNervous system disorders | 13/92 | 2/34 | 2/35 |
| Decreased AppetiteMetabolism and nutrition disorders | 10/92 | 0/34 | 0/35 |
| InsomniaPsychiatric disorders | 10/92 | 0/34 | 0/35 |
| DizzinessNervous system disorders | 8/92 | 0/34 | 0/35 |
| Dry MouthGastrointestinal disorders | 6/92 | 1/34 | 0/35 |
| NauseaGastrointestinal disorders | 2/92 | 2/34 | 1/35 |
| FatigueGeneral disorders | 4/92 | 2/34 | 1/35 |
| DiarrheaGastrointestinal disorders | 5/92 | 0/34 | 0/35 |
| VomitingGastrointestinal disorders | 4/92 | 0/34 | 0/35 |
| AnxietyPsychiatric disorders | 4/92 | 1/34 | 0/35 |
| Age, Continuous(years) | Overall |
|---|---|
| Mean | 42.3 ± 9.11 |
| Age, Customized(Participants) | Overall |
|---|---|
| <18 years | 0 |
| Between 18 and 55 years | 92 |
| >55 years | 0 |
| Sex: Female, Male(Participants) | Overall |
|---|---|
| Female | 30 |
| Male | 62 |
| Region of Enrollment(Participants) | Overall |
|---|---|
| United States | 92 |
Ran from Sep 2009 to primary completion in Jan 2011, 16 months.
Results were first posted in Feb 2012, 1 year 1 month after primary completion.
Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 16 months is below that.
Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisdexamfetamine